Case Report
high doses of triple vasopressors (noradrenaline, adrenaline, and vasopressin). At this point of time, a decision to initiate peripheral VA ECMO was made. A 17-French cannula was inserted into the left femoral artery and a 19-French cannula into the right femoral vein. An additional 7-French cannula was placed in the left femoral artery to facilitate distal perfusion. VA ECMO was initiated at a flow of 3.7 L/min, and within 2 h, her vasopressor requirement decreased significantly [ Table 2 ]. Over the next 6 h, her acidosis settled and lactate levels decreased. By the 2 nd day, despite significant improvement in her hemodynamics, her oxygenation worsened with clinical and radiological features suggestive of acute respiratory distress syndrome. By the 4 th day, she was changed over to a veno-venous ECMO, and by the 5 th day, it was decannulated.
She was successfully weaned off the ventilator and extubated by the 8 th day and discharged from the hospital on the 11 th day.
Case 2
A 19-year-old male was admitted to the ICU about 24 h after having ingested 30 tablets each of amlodipine 5 mg and atenolol 25 mg. He was resuscitated in another hospital before the transfer. 60 units IV bolus followed by 60 U/h IV infusion 40 units IV bolus followed 40 units/h IV infusion 40 units IV bolus followed 40 units/h IV infusion Calcium Gluconate 30 ml IV bolus followed by 30 ml/h infusion 30 ml IV bolus followed by 30 ml/h infusion -Glucagon 5 mg IV bolus followed by 5 mg/h infusion 5 mg IV bolus followed by 5 mg/h infusion 5mg IV bolus followed by 5mg/h infusion Lipid Emulsion 90 ml IV bolus followed 900 ml IV over 2 h 100 ml IV bolus followed by 500ml over 2 h 90ml IV bolus followed by 900ml IV -+ --indicates absent; + indicates present; Recommended dose for insulin: 1 unit/kg IV bolus followed by 0.5-10 mg/kg/h infusion; Recommended dose for glucagon: 5-10 mg IV bolus followed by 2-10 mg/h infusion; Recommended dose for lipid emulsion -1.5mL/kg of 20% lipid as a bolus, repeated up to twice as needed, followed by an infusion of 0.25mL/kg/min for 30-60 minutes. The maximum total dose administered per 24 hour of 12.5mL/kg.; Recommended dose for calcium: 10-20 ml of 10% calcium chloride or 30-60 ml of 10% calcium gluconate, to be repeated every 15-20 min, up to four doses. Calcium can also be given as a continuous infusion 0.2-0.4 ml/kg/h of 10% calcium chloride or 0.6-1.2 ml/kg/h of 10% calcium gluconate. ECMO: Extracorporeal membrane oxygenation; APACHE: Acute Physiology and Chronic Health Evaluation; ICU: Intensive Care Unit; MAP: Mean arterial pressure On arrival to the ICU, he was on high dose of multiple vasopressors (noradrenaline, adrenaline, dopamine, and vasopressin) and had a temporary transvenous pacer in situ. His HR was 78/min, in sinus rhythm and well above the pacing rate; BP was 90/50 mmHg; SpO 2 98% on 40% FiO 2 ; and central venous pressure was 24 mmHg with cold peripheries. Echocardiogram showed normal LV function. Baseline ABG showed metabolic acidosis with a pH of 7.16 and lactate level of 4.59 mmol/dL. He was resuscitated with standard doses of IV calcium gluconate, intralipid insulin, glucagon, and sodium bicarbonate [ Table 1 ]. Despite 14 h of aggressive resuscitation, his vasopressor requirements increased and his shock worsened leading to initiation of a peripheral VA ECMO. The cannulation technique was similar to that used for case 1 and the ECMO flow was set at 4 L/min. Over the next 24 h, his vasopressor requirements reduced significantly [ Table 2 ] and he was completely weaned off vasopressor support. Urine output and lactate levels improved immediately. By the 4 th day, the calcium, insulin, and glucagon infusions were sequentially stopped. ECMO was decannulated on the 5 th day, and he was extubated on the 6 th day. However, on the 7 th day, he developed swelling and tenderness in the left lower limb over the arterial cannulation site, requiring fasciotomy for impending compartment syndrome. He responded well to treatment and was moved out of ICU on the 13 th day.
Case 3
A 17-year-old female was admitted following ingestion of multiple drugs (propranolol 40 mg -10 tablets; fluphenazine 10 mg -10 tablets; amitriptyline 10 mg -4 tablets; gabapentin 300 mg -2 tablets). Her initial resuscitation was done at an outside hospital.
She arrived to our hospital 36 h following ingestion of the drugs, intubated, and in severe shock. Evaluation revealed a left-sided pneumothorax for which intercostal drain was placed. She was volume resuscitated and initiated on the standard doses of IV calcium gluconate, insulin infusion, glucagon and intralipids [ Table 1 ]. Her hemodynamics improved within 12 h, with medical therapy. However, she went into supraventricular tachycardia followed by pulseless ventricular tachycardia that required 30 min of resuscitation for return of spontaneous circulation (ROSC). This episode was followed by refractory shock necessitating initiation of peripheral VA ECMO, which had to be converted into a central VA ECMO, with additional 14-French LV vent cannula as flows >2.5 L/min could not be achieved. Her vasopressor requirements decreased almost immediately [ Table 2 ]. By the 4 th day, her hemodynamics improved to a level that the ECMO was weaned off and decannulated with minimal vasopressor support. Her stay in the ICU was a stormy and complicated by increased drainage from her chest drain requiring re-exploration, development of multiorgan failure -acute renal shutdown requiring renal replacement therapy, ischemic hepatitis, coagulopathy requiring multiple blood product transfusions, and ventilator-associated pneumonia requiring broad-spectrum antibiotics. She required renal replacement therapy till day 10 and was extubated on day 10. On the 20 th day, she was shifted out of ICU and discharged from hospital on the 29 th day.
dIscussIon
The toxic effects of cardiac medication overdose are primarily an extension of their pharmacological activity. Beta blockers and CCB inhibit calcium influx into the cells, though by different mechanisms. [5, 6] The hemodynamic effects seen in their overdose are due to impaired cardiac contractility, vasoplegia, and/or rhythm disturbances.
The cornerstone of medical management for these drug overdoses consists of limiting their absorption and hemodynamic support until they are metabolized and eliminated from the body. Gastric decontamination with activated charcoal to limit the absorption can be attempted when done early. [7] Volume resuscitation with fluids to overcome the relative hypovolemia associated with vasodilation and inotropic/vasopressor use are the mainstay. In CCB overdose, calcium infusion can be initiated in an attempt to overcome the calcium channel antagonism. The increased transcellular calcium gradient drives calcium intracellularly and antagonizes the effect of CCBs. [8] In patients not responding to fluid resuscitation and inotropic support IV glucagon can be tried. Glucagon exerts its inotropic effects by activating adenylyl cyclase directly. The recommended dose is 5-10 mg IV bolus followed by infusion at the rate of 2-10 mg/h. The potential adverse effects include dose-dependent nausea, vomiting, hyperglycemia, and allergic reactions. [6] High-dose insulin also has been used, and this improves the hemodynamics by exerting a direct inotropic effect and also by improving the carbohydrate metabolism in the myocardium. [9] The recommended dose is 1 U/kg/h following a bolus of 1 U/kg. The infusion rate may be increased by 2 U/kg/h every 10 min to a maximum dose of 10 U/kg/min. [10] Close monitoring of serum glucose, potassium, magnesium, and phosphorus is very important. Another drug used is IV lipid emulsions, and this creates an expanded lipid phase in the blood and traps the tissue-bound drugs to negate the toxic effects. [11] It is administered as 20% intralipid at a dose of 1.5 ml/kg bolus followed by infusion of 0.25-0.5 ml/kg/min. [12] In this case series of three patients, various combinations of cardioactive drug overdoses have been described. Patient 1 had taken CCB, patient 2 presented with a combination of beta blocker and CCB, while patient 3 had taken a combination of beta blocker and other membrane stabilizing agents. Compared to other reported case series, this series had patients who were younger [13] and none of them had any major comorbidities which could potentiate the cardiotoxic effects of the drugs. The APACHE score of the patients were 19, 31, and 23, respectively.
Two of the patients were absolutely refractory to medical therapy and was in refractory shock with high lactate levels. Even though the third patient had transient hemodynamic response, she had an arrhythmic cardiac arrest 12 h into the medical therapy. The average time of arrival to the hospital was 18 h. All of them received primary aid in another hospital and was referred for further care.
The principle of extracorporeal support in cardiovascular medication overdose is to support the hemodynamics and vital organ perfusion, until the medications have been eliminated from the system. [13] [14] [15] The ECMO system used in this case series was Maquet Permanent Life Support System which include Rotaflow centrifugal pump, preconnected heparin and albumin-coated polyvinyl tubing, and quadrox-i membrane oxygenator with an integrated heat exchange system. All patients were heparinized just before insertion of vascular cannula and heparin infusion was continued to maintain activated clotting time of 160-180 s. ECMO flow was initiated at 3.5-4 L along with vasopressors support to maintain adequate mean arterial pressure. All patients were mechanically ventilated and other organ supports were provided as indicated. Once the hemodynamics improved, ECMO flow was gradually reduced and hemodynamic stability was assessed. If patient remained hemodynamically stable, ECMO was weaned off.
The average admission to ECMO initiation time in this series was 15.3 h. Daubin et al., in a larger series of seventeen patient, reported admission to ECMO initiation time of 6.4 ± 7.0 h. [16] One of the patients, in this series, had ECMO initiated only after restoration of ROSC from cardiac arrest, and this patient went on to develop multiorgan failure requiring organ supports including renal replacement therapy. In all the three patients, percutaneous peripheral arterial cannulations were performed in the bedside at the ICU. However, in one patient, adequate flow could not be achieved with the peripheral cannulation, and hence, central cannulation was done in the operating room. The average duration of ECMO support in this series was 74 h. In the series reported by Daubin et al., the duration of ECMO flow was 4.5 ± 2.4 days. [15] There was a rapid decrease in the inotropic requirements after initiation of ECMO, however, a small dose was continued to maintain a target mean arterial pressure. These findings are very similar to other reports.
In another case report, Weinberg et al. described successful use of ECMO in two patients with refractory vasodilatory shock associated with amlodipine poisoning. [16] Like any other invasive devices, ECMO too comes with its set of complications. Limb ischemia is a well-documented complication of ECMO support. Daubin et al. reported ischemic complications in 10 of the 17 patients in their case series. [15] However, Mégarbane et al. have reported lesser ischemic complications. [17] One of the three patients in this case series developed limb ischemia in the cannulation side requiring fasciotomy, despite ensuring distal limb perfusion with additional distal cannulation. The other major reported complication of ECMO support is bleeding. In this case series, the patient who had central cannulation had major mediastinal bleeding requiring re-exploration and need for multiple blood products. Despite these complications all three patients survived and were discharged successfully.
conclusIon
Based on the limited evidence, there may be a role for the use of VA ECMO in patients with severe cardioactive drug overdose refractory to the medical therapy. Early initiation of ECMO support before organ failure or cardiac arrest sets in should be contemplated and may ensure the better overall outcome.
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